Researchers are testing the ChAdOx BDBV vaccine on 50 volunteers to address the Bundibugyo ebolavirus strain currently spreading in the DRC.

A Phase 1b trial of the immunotherapy IBC-Ab002 has successfully met safety endpoints, marking a potential shift in treating Alzheimer's as a systemic immune disorder.

Health officials have launched clinical trials to evaluate treatments and preventive drugs for the Bundibugyo strain of the Ebola virus. The studies target both active infections and post-exposure prophylaxis to combat the ongoing outbreak.

Researchers have unveiled mid-stage trial results for diranersen, an experimental drug that reduces abnormal tau production in Alzheimer’s patients.

Confirmed Ebola cases in the Democratic Republic of the Congo have reached 1,502, creating a public health crisis across the nation's eastern provinces. Medical authorities face significant containment hurdles as the virus spreads through areas affected by conflict.

Health authorities have launched the PARTNERS clinical trial in the Democratic Republic of Congo to evaluate monoclonal antibodies and remdesivir. The study aims to determine the efficacy of these treatments against the rare Bundibugyo Ebola virus strain.

Immunotherapy is shifting the survival landscape for patients with advanced cancers by training the immune system to target malignant cells. While these treatments have led to significant clinical breakthroughs, experts emphasize that sustainable research funding remains vital.